FDAsafety guidance72% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Veterans with Opioid Use Disorder.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Substance Use Disorder · Opioid Use Disorder
- Sub-indication
- Pain
Related signal: VA Study to Test Values-Based Intervention for Veterans in Buprenorphine Treatment